NewLink Genetics Corporation (NASDAQ:NLNK)
NewLink Genetics Corporation (NASDAQ:NLNK) gained 17.5% today on over five times the average daily volume. NewLink Genetics announced that it will be presenting at the 2017 American Association of Cancer Research annual meeting. Experts claim that when a firm agrees to participate in such an event, there is a high likelihood that they will be presenting positive news on one of their drug or treatment candidates.
NewLink Genetics (NASDAQ:NLNK) is a biopharmaceutical company at the forefront of discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of cancer patients. NewLink Genetics’ product candidates are designed to harness multiple components of the immune system to combat cancer.
Tuesday, February 28, 2017, NewLink Genetics Corp. (NASDAQ:NLNK) reported Q4 and full year earnings. NewLinks lost $13.5 million in its fourth quarter. The Ames, IA-based company said it had a loss of $0.46/share. The results exceeded Wall Street expectations. The average of analysts estimates of four analysts was reported to be a loss of $0.66/share. NewLink Genetics posted revenue of $12.7 million in the period – beating analyst estimates of $4.3 million. NewLink posted a yearly loss of $85.2 million, or $2.94 per share. Revenue was reported as $35.8 million.
NewLink Genetics Corp. (NASDAQ:NLNK) shares have risen 38.2% this week and 92% YTD. NLNK shares started the year around $10 and have risen in value each month for the past three months but are still over 4% from their 52-week highs. Of the six firms that follow NewLink Genetics Corp. (NASDAQ:NLNK), four rate the shares as a “Strong Buy” and two rate NLNK shares as a “Hold”.
|Last Price a/o 5:08 PM EST||$ 19.73|
|Market Cap (mlns)||$ 578.88|
|Shares Outstanding (mlns)||29.34|
|Share Float (mlns)||21.62|
|Short Interest Ratio||8.14|
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.
About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading.